A randomized phase I / II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Yoko YoshimaruKatsuya NagaokaKentaro TanakaSatoshi NaraharaHiroki InadaSotaro KuranoTakayuki TokunagaEstuko IioTakehisa WatanabeHiroko SetoyamaMasakuni TateyamaKoji YoshidaTakuya TsunodaYusuke NakamuraMotohiko TanakaYutaka SasakiYasuhito Tanaka

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

Immunotherapy with peptides vaccines targeting VEGFR1 and VEGFR2 was well tolerated with no serious adverse events. It also effectively induced peptide-specific CTLs in patients with unresectable hepatocellular carcinoma. This article is protected by copyright. All rights reserved.

Keyphrases

vascular endothelial growth factor
endothelial cells
high glucose
diabetic rats
cancer therapy
squamous cell carcinoma
drug induced
oxidative stress
liver metastases